Blue Water Vaccines Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Blue Water Vaccines Inc (BWV) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Blue Water Vaccines Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 125M combined for tracked competitors (0.5% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-89.4% annualized vs trailing 12 months), vs accelerating (+3.5%) for its tracked peer group.
- Growth: Blue Water Vaccines Inc generated -83.9% revenue growth year over year in Q2 2026, vs -73.3% for its tracked competitors combined.
- Profitability: Its -16,748.3% net margin compares with -928.4% for the peer group.
- Peer revenue share: Blue Water Vaccines Inc accounted for 0.1% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.06M compares with $0.12M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BWV Sales vs. its Competitors, Q2 2026
Blue Water Vaccines Inc reported revenue contraction of 83.92 % year on year in Q2 2026, below its competitors' combined revenue change of -73.28 %.
With a net margin of -16,748.27 %, Blue Water Vaccines Inc reported lower profitability than its competitors (-928.43 %).
Blue Water Vaccines Inc generated 0.05 % of the combined sales of its peer group, down from 0.09 % a year earlier.
Blue Water Vaccines Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Blue Water Vaccines Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Blue Water Vaccines Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Blue Water Vaccines Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -83.9% for Blue Water Vaccines Inc. Blue Water Vaccines Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Blue Water Vaccines Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Blue Water Vaccines Inc | No | No | No | No |
| Competitors combined (9) | ||||
| High-Confidence Competitors (1) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) | 75.00 % (6 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BWV Stock Performance relative to its Competitors
BWV Stock Performance relative to High-Confidence Competitors
BWV Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Climb Bio Inc | 282.9% | Outperformed |
| 2 | Zymeworks Inc | 282.9% | Outperformed |
| 3 | Cytokinetics Incorporated | 282.9% | Outperformed |
| 4 | Cytodyn inc | 282.9% | Outperformed |
| 5 | Annovis Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Blue Water Vaccines Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Blue Water Vaccines Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Blue Water Vaccines Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Blue Water Vaccines Inc | 0.40 | 0.65 |
| Cytokinetics Incorporated | 8,738.81 | 67.67 |
| Zymeworks Inc | 1,979.58 | 37.13 |
| Climb Bio Inc | 894.05 | - |
| Cytodyn inc | 271.27 | - |
| Annovis Bio Inc | 51.78 | - |
| SUBTOTAL | 11,985.77 | 129.79 |
Sign in to see all competitors of Blue Water Vaccines Inc.
Sources: Blue Water Vaccines Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Blue Water Vaccines Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Blue Water Vaccines Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Proteomedix | Named by the company | 85% |
| Novartis AG | Named by the company | 85% |
| St. Jude Children’s Research Hospital | Named by the company | 85% |
| Onconetix | Named by the company | 85% |
| Zydus Life Sciences | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Blue Water Vaccines Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Blue Water Vaccines Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Blue Water Vaccines Inc | 0 | 58,712 | -790,689 |
| Cytokinetics Incorporated | 8,739 | 100,550 | -1,328,383 |
| Zymeworks Inc | 1,980 | 140,633 | -568,152 |
| Climb Bio Inc | 894 | - | -1,987,034 |
| Cytodyn inc | 271 | - | -3,049,929 |
| Annovis Bio Inc | 52 | - | -6,190,533 |
| PEERS TOTAL | 11,985 | 123,113 | -1,195,089 |
Sign in to see all peers for Blue Water Vaccines Inc.
Blue Water Vaccines Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Blue Water Vaccines Inc | GB 100.00 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Blue Water Vaccines Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Blue Water Vaccines Inc's industry classification, broader than the peer set above. Market cap in millions of $.Blue Water Vaccines Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 823, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,058,838 | 19.26 % |
| 2 | Johnson and Johnson | 663,585 | 12.07 % |
| 3 | Beone Medicines Ltd | 552,468 | 10.05 % |
| 4 | Abbvie Inc | 471,582 | 8.58 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Blue Water Vaccines Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Blue Water Vaccines Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2023-12-21.
Blue Water Vaccines Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 80.40 % | 64.89 % (avg) | +15.5 pp |
| Operating Margin | -2,525.03 % | industry median | -2,471.4 pp |
| EBITDA Margin | -1,555.64 % | -7.21 % (avg) | -1,548.4 pp |
| Capital Intensity (Capex / Revenue) | - | 4.92 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Blue Water Vaccines Inc's Strategic Group Map
Every company in Blue Water Vaccines Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Blue Water Vaccines Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Blue Water Vaccines Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 823 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Blue Water Vaccines Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Blue Water Vaccines Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Blue Water Vaccines Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Blue Water Vaccines Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Blue Water Vaccines Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 2,471.4 points below the industry median.
- Return on equity 95.7 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-89.4% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of tracked competitors (75.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Blue Water Vaccines Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Blue Water Vaccines Inc | 0.50 | 0.58 | 0.01 |
| Cytokinetics Incorporated | 3.00 | 5.44 | - |
| Zymeworks Inc | 3.17 | 7.32 | - |
| Climb Bio Inc | 5.19 | 22.65 | - |
| Cytodyn inc | 0.20 | 0.26 | - |
| Annovis Bio Inc | 2.56 | 2.78 | - |
Sign in to see all peers for Blue Water Vaccines Inc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Blue Water Vaccines Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Blue Water Vaccines Inc | Q2 2026 | -83.9 % | - |
| Cytokinetics Incorporated | Q2 2026 | -57.1 % | - |
| Zymeworks Inc | Q2 2026 | -90.6 % | - |
| Climb Bio Inc | Q2 2026 | - | - |
| Cytodyn inc | Q2 2026 | - | - |
| Annovis Bio Inc | Q2 2026 | - | - |
| PEERS TOTAL | -74.3 % | - |
Sign in to see all peers for Blue Water Vaccines Inc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Blue Water Vaccines Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Blue Water Vaccines Inc | Q2 2026 | -64.4 % | - |
| Cytokinetics Incorporated | Q2 2026 | - | +4.6 % |
| Zymeworks Inc | Q2 2026 | - | - |
| Climb Bio Inc | Q2 2026 | - | +237.7 % |
| Cytodyn inc | Q2 2026 | - | - |
| Annovis Bio Inc | Q2 2026 | - | - |
Sign in to see all peers for Blue Water Vaccines Inc.
Blue Water Vaccines Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Blue Water Vaccines Inc | - | - | - |
| Cytokinetics Incorporated | - | - | - |
| Zymeworks Inc | - | - | - |
| Climb Bio Inc | - | - | - |
| Cytodyn inc | - | - | - |
| Annovis Bio Inc | - | - | - |
Sign in to see all peers for Blue Water Vaccines Inc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Blue Water Vaccines Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Blue Water Vaccines Inc | - | 0.63 |
| Cytokinetics Incorporated | - | 129.14 |
| Zymeworks Inc | - | 53.32 |
| Climb Bio Inc | - | - |
| Cytodyn inc | - | - |
| Annovis Bio Inc | - | - |
| PEERS AVERAGE | - | 92.35 |
Sign in to see all peers for Blue Water Vaccines Inc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.